葛根素对高脂饮食诱导小鼠非酒精性脂肪性肝病的改善作用及其机制

doi:10.13481/j.1671-587X.20260106

Abstract

Abstract:

Objective To explore the ameliorative effect of puerarin （Pue） on non-alcoholic fatty liver disease （NAFLD） induced by high-fat diet in the mice， and to clatrify its possible mechanism. Method A total of 36 C57BL/6J mice were randomly divided into control group， model group， low dose of Pue group （20.0 mg·kg^-1）， medium dose of Pue group （40.0 mg·kg^-1）， high dose of Pue group （80.0 mg·kg^-1）， and positive drug group ［atorvastatin calcium （AT） group］（10.0 mg·kg^-1 AT）， with 6 mice in each group. Except for control group， in which the mice were given normal diet， all of the mice in the other groups were fed with high-fat diet to establish the NAFLD models. The body weights of the mice in various groups were measured， and the liver indexes was calculated； the pathomorphology of liver tissue of the mice in various groups was observed by HE staining method. The total cholesterol （TC） and triglyceride （TG） levels in serum and liver tissue， alanine aminotransferase （ALT） and aspartate aminotransferase （AST） levels in serum， the malondialdehyde （MDA） levels， superoxide dismutase （SOD） and glutathione peroxidase （GSH-Px） activities in liver tissue， as well as interleukin-6 （IL-6）， interleukin-1β （IL-1β）， and tumor necrosis factor-α （TNF-α） levels in liver tissue of the mice in various groups were detected by commercial biochemical assay kits. Within the framework of network pharmacology， the potential therapeutic targets of Pue were predicted by integrating multiple databases， including PubChem and Swiss Target Prediction， and other publicly available resources. These targets were cross-referenced with NAFLD-associated disease targets retrieved from GeneCards and other platforms， enabling the construction of a high-confidence protein-protein interaction （PPI） network. Subsequently， Gene Ontology （GO） function and Kyoto Encyclopedia of Genes and Genomes （KEGG） signaling pathway enrichment analyses were performed to elucidate the therapeutic mechanisms of Pue in NAFLD intervention； Western blotting method was used to detect the protein expression levels of Kelch-like ECH-associated protein 1 （Keap1）， nuclear factor erythroid 2-related factor 2 （Nrf2）， heme oxygenase-1 （HO-1）， and quinone oxidoreductase 1 （NQO1） in liver tissue of the mice in various groups. Additionally， 30 mice were randomly divided into control group，?model group， Pue group （80.0 mg·kg^-1 Pue gavage）， model+Nrf2 inhibitor ML385 group （30.0 mg·kg^-1 ML385 intraperitoneal administration）， and Pue+ML385 group?（80.0 mg·kg^-1 Pue gavage， 30 mg·kg^-1 ML385 intraperitoneal administration）. After treatment， the oxidative stress markers， inflammatory cytokines， and protein expression levels metioned above were detected. Results Compared with control group， the body weight and liver index of the mice in model group were significantly increased （P<0.01）； compared with model group， the body weight and liver index of the mice in low， medium， and high doses of Pue groups and AT group were significantly decreased （P<0.05 or P<0.01）. The HE staining results showed compared with control group there was significant lipid accumulation and pathological damage in liver tissue of the mice in model group； compared with model group， the accumulation of lipid droplets and pathological damage in liver tissue of the mice in low， medium， and high doses of Pue groups and AT group were improved to varying degrees. Compared with control group， the levels of TC， TG， IL-6， IL-1β， TNF-α， and MDA in liver tissue of the mice in the model group， as well as the serum TC， TG， ALT， and AST levels were significantly increased （P<0.01）， while the activities of SOD and GSH-Px in liver tissue were significantly decreased （P<0.01）； compared with model group， the levels of TC， TG， IL-6， IL-1β， TNF-α， and MDA in liver tissue， as well as the levels of TC， TG， ALT， and AST in serum of the mice in low， medium， and high doses of Pue groups and AT group were significantly decreased （P<0.05 or P<0.01）， while the activities of SOD and GSH-Px in liver tissue were significantly increased （P<0.05 or P<0.01）. The Network pharmacology analysis results identified the core targets of Pue in treating NAFLD， including Nrf2， TNF， and IL-6， and predicted that Pue may exert its effects through regulating oxidative stress， inflammation， and apoptosis pathways. The Western blotting results showed that compared with control group， the expression level of Keap1 protein in liver tissue of the mice in model group was increased （P<0.01）， while the expression levels of Nrf2， HO-1， and NQO1 proteins were decreased （P<0.01）； compared with model group， the expression levels of Keap1 protein in liver tissue of the mice in low， medium， and high doses of Pue groups and AT group were decreased （P<0.05 or P<0.01）， while the expression levels of Nrf2， HO-1， and NQO1 proteins were increased （P<0.05 or P<0.01）. After intervention with Nrf2 inhibitor ML385， compared with Pue group， the levels of IL-6， IL-1β， TNF-α， and MDA in liver tissue of the mice in Pue+ML385 group were significantly increased （P<0.05）， while the activities of SOD and GSH-Px were significantly decreased （P<0.05 or P<0.01）， the expression level of Keap1 protein in liver tissue was increased （P<0.01）， and the expression levels of Nrf2， HO-1， and NQO1 proteins were decreased （P<0.01）. Conclusion Pue can improve the lipid metabolism and liver function in the NAFLD mice， alleviate the liver damage， enhance the liver tissue antioxidant capacity， and reduce the release of inflammatory factors. Its mechanism may be related to the activation of the Keap1/Nrf2/HO-1 signaling pathway.

Key words: Puerarin, Non-alcoholic fatty liver disease, Oxidative stress, Inflammation, Nuclear factor erythroid 2-related factor 2

CLC Number:

R285.5

Sitong CHEN,Dan YANG,Qingjie LI,Xiaolei TANG,Han WANG,Yangyang LIU,Tiejun LIU. Ameliorative effect of puerarin on non-alcoholic fatty liver disease induced by high-fat diet in mice and its mechanism[J].Journal of Jilin University(Medicine Edition), 2026, 52(1): 44-55.

Figures/Tables 11

Tab.1

Fig. 1

Tab.2

Tab.3

Tab.4

Tab.5

Fig. 2

Fig. 3

Tab.6

Tab.7

Fig. 4

References 32

[1]	AMORIM R， SOARES P， CHAVARRIA D， et al. Decreasing the burden of non-alcoholic fatty liver disease： From therapeutic targets to drug discovery opportunities ［J］. Eur J Med Chem， 2024， 277（15）： 116723.
[2]	WEI S， WANG L， EVANS P C， et al. NAFLD and NASH： etiology， targets and emerging therapies ［J］. Drug Discov Today， 2024， 29（3）： 103910.
[3]	HAN S K， BAIK S K， KIM M Y. Non-alcoholic fatty liver disease： Definition and subtypes ［J］. Clin Mol Hepatol， 2023， 29（）： S5-S16.
[4]	THIRUVENGADAM M， VENKIDASAMY B， SUBRAMANIAN U， et al. Bioactive compounds in oxidative stress-mediated diseases： targeting the NRF2/ARE signaling pathway and epigenetic regulation ［J］. Antioxidants （Basel）， 2021， 10（12）：1895.
[5]	YANG K， YU X， GUO Z， et al. PIM1 alleviated liver oxidative stress and NAFLD by regulating the NRF2/HO-1/NQO1 pathway ［J］. Life Sci， 2024， 349（14）： 122714.
[6]	PENGNET S， SUMARITHUM P， PHONGNU N， et al. Naringin attenuates fructose-induced NAFLD progression in rats through reducing endogenous triglyceride synthesis and activating the Nrf2/HO-1 pathway ［J］. Front Pharmacol， 2022， 13： 1049818.
[7]	WU Q， LI P， LI X， et al. Pueraria extract ameliorates alcoholic liver disease via the liver-gut-brain axis： focus on restoring the intestinal barrier and inhibiting alcohol metabolism ［J］. J Agric Food Chem， 2024， 72（44）： 24449-24462.
[8]	YANG M， XIA L， SONG J， et al. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation ［J］. Lipids Health Dis， 2023， 22（1）： 202-217.
[9]	YEN P T， HUANG S E， HSU J H， et al. Anti-Inflammatory and anti-oxidative effects of Puerarin in postmenopausal cardioprotection： roles of Akt and heme oxygenase-1［J］. Am J Chin Med， 2023， 51（1）： 149-168.
[10]	ZHOU W， HE H， WEI Q， et al. Puerarin protects against acetaminophen-induced oxidative damage in liver through activation of the Keap1/Nrf2 signaling pathway ［J］. Food Sci Nutr， 2023， 11（10）： 6604-6615.
[11]	ZHOU J， ZHANG N， ALDHAHRANI A， et al. Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation， oxidative stress， and inflammation ［J］. Front Immunol， 2022， 13： 956688.
[12]	DINIZ T A， DE LIMA JUNIOR E A， TEIXEIRA A A， et al. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice ［J］. Life Sci， 2021， 266： 118868.
[13]	LIU J， SUN J， YU J， et al. Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism ［J］. NPJ Biofilms Microbiomes， 2023， 9（1）： 29-39.
[14]	GONG P， WANG J， WANG S， et al. Metabolomic analysis of the Puerarin hypoglycemic activity via AMPK-mTOR and PPARγ-NF-κB signaling pathways ［J］. Phytomedicine， 2024， 130： 155546.
[15]	HEEREN J， SCHEJA L. Metabolic-associated fatty liver disease and lipoprotein metabolism ［J］. Mol Metab， 2021， 50（8）： 101238.
[16]	FLESSA C M， NASIRI-ANSARI N， KYROU I， et al. Genetic and diet-induced animal models for non-alcoholic fatty liver disease （NAFLD） research ［J］. Int J Mol Sci， 2022， 23（24）： 15791.
[17]	ZHENG Y， WANG S， WU J， et al. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease： new insights from pathogenic mechanisms to clinically targeted therapy ［J］. J Transl Med， 2023， 21（1）： 510-530.
[18]	GUO X， YIN X， LIU Z， et al. Non-alcoholic fatty liver disease （NAFLD） pathogenesis and natural products for prevention and treatment ［J］. Int J Mol Sci， 2022， 23（24）： 15489.
[19]	ALLAMEH A， NIAYESH-MEHR R， ALIARAB A， et al. Oxidative stress in liver pathophysiology and disease ［J］. Antioxidants （Basel）， 2023， 12（9）： 1653-1675.
[20]	ZHU L， LI B， CHEN D， et al. sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes ［J］. Life Sci， 2022， 296（9）： 120438.
[21]	KARKUCINSKA-WIECKOWSKA A， SIMOES I C M， KALINOWSKI P， et al. Mitochondria， oxidative stress and nonalcoholic fatty liver disease： A complex relationship［J］. Eur J Clin Invest， 2022， 52（3）： e13622.
[22]	李岫滟，雷娜，宋虹霏，等. 内质网应激在非酒精性脂肪性肝病中的作用及相关靶向治疗［J］. 临床肝胆病杂志， 2024， 40（11）： 2300-2305.
[23]	FREDRICKSON G， BARROW F， DIETSCHE K， et al. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH［J］. Mol Metab， 2021， 53（11）： 101270.
[24]	DUAN Y， PAN X， LUO J， et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease［J］. Front Immunol， 2022， 13： 880298.
[25]	YANG C W， LIU H M， CHANG Z Y， et al. Puerarin modulates hepatic farnesoid X receptor and gut microbiota in high-fat diet-induced obese mice［J］. Int J Mol Sci， 2024， 25（10）： 5274-5299.
[26]	LI L， YANG L， YANG L， et al. Network pharmacology： a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine［J］. Chin Med， 2023， 18（1）： 146-164.
[27]	段明秀，陈新利，常伟宇，等. 非酒精性脂肪性肝病多组学研究现状［J］. 临床肝胆病杂志， 2024， 40（6）： 1240-1247.
[28]	ABDULAAL W H， OMAR U M， ZEYADI M， et al. Modulation of the crosstalk between Keap1/Nrf2/HO-1 and NF-κB signaling pathways by Tomatidine protects against inflammation/oxidative stress-driven fulminant hepatic failure in mice［J］. Int Immunopharmacol， 2024， 130： 111732.
[29]	DING C， WU Y， ZHAN C， et al. Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation［J］. Int Immunopharmacol， 2024， 141（16）： 112853.
[30]	LI B， NASSER M I， MASOOD M， et al. Efficiency of traditional Chinese medicine targeting the Nrf2/HO-1 signaling pathway［J］. Biomed Pharmacother， 2020， 126（6）： 110074.
[31]	FANG Q L， QIAO X， YIN X Q， et al. Flavonoids from Scutellaria amoena C. H. Wright alleviate mitochondrial dysfunction and regulate oxidative stress via Keap1/Nrf2/HO-1 axis in rats with high-fat diet-induced nonalcoholic steatohepatitis［J］. Biomed Pharmacother， 2023， 158： 114160.
[32]	DONG H， ZHAO Y， TENG H， et al. Pueraria lobata antioxidant extract ameliorates non-alcoholic fatty liver by altering hepatic fat accumulation and oxidative stress［J］. J Ethnopharmacol， 2024， 333（19）： 118468.

Group	Body weight (m/g)	Liver index (η/%)
Control	28.87±0.89	4.34±0.20
Model	44.37±0.36^*	7.72±0.44^*
Pue
Low dose	38.52±0.57^△	5.66±1.54^△
Medium dose	37.57±0.62^△	5.07±0.44^△△
High dose	36.63±0.98^△△	5.05±0.69^△△
AT	35.32±0.85^△△	4.71±0.57^△△

Group	TC level in liver tissue [m_B/(mmol·g^-1)]	TG level in liver tissue [m_B/(mmol·g^-1)]	TC level in serum [c_B/(mmol·L^-1)]	TG level in serum [c_B/(mmol·L^-1)]
Control	0.29±0.05	0.55±0.05	1.52±0.08	0.63±0.05
Model	0.73±0.06^*	1.21±0.05^*	5.95±0.11^*	1.70±0.08^*
Pue
Low dose	0.60±0.07^△	1.09±0.06^△	5.36±0.56^△	1.49±0.10^△
Medium dose	0.59±0.06^△	0.82±0.08^△△	3.46±0.32^△△	1.06±0.10^△△
High dose	0.53±0.10^△△	0.67±0.05^△△	2.84±0.27^△△	0.86±0.06^△△
AT	0.37±0.08^△△	0.65±0.06^△△	2.70±0.40^△△	0.78±0.06^△△

Group	ALT	AST
Control	37.13±4.67	29.04±3.96
Model	103.40±14.87^*	97.76±9.84^*
Pue
Low dose	92.30±8.96^△	89.67±8.30^△
Medium dose	75.20±8.07^△△	60.36±7.26^△△
High dose	51.01±7.61^△△	57.90±7.55^△△
AT	50.79±7.15^△△	54.38±5.64^△△

Group	MDA [m_B/(μmol·g^-1)]	SOD [λ_B/(U·mg^-1)]	GSH-Px [λ_B/(U·mg^-1)]
Control	1.36±0.08	140.48±7.39	126.38±6.54
Model	2.66±0.23^*	57.37±6.94^*	54.01±5.36^*
Pue
Low dose	2.33±0.26^△	72.80±4.92^△	67.12±9.16^△
Medium dose	2.00±0.12^△△	89.46±6.29^△△	92.87±5.81^△△
High dose	1.87±0.11^△△	106.12±9.04^△△	106.02±6.96^△△
AT	1.68±0.18^△△	120.15±9.42^△△	109.61±7.18^△△

Group	IL-6	IL-1β	TNF-α
Control	15.77±1.12	12.42±0.72	115.76±8.35
Model	29.69±3.27^*	31.25±4.28^*	195.25±8.99^*
Pue
Low dose	24.59±1.43^△	26.24±1.34^△	178.74±6.43^△
Medium dose	23.27±2.80^△△	25.77±1.72^△	165.43±8.27^△△
High dose	21.82±2.80^△△	22.73±2.52^△△	143.23±7.47^△△
AT	22.11±3.08^△△	21.48±3.45^△△	146.31±12.24^△△

Ameliorative effect of puerarin on non-alcoholic fatty liver disease induced by high-fat diet in mice and its mechanism

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 32

Related Articles 15

Metrics

Comments

Recommended 0

Group	MDA [m_B/（μmol·g^-1）]	SOD [λ_B/（U·mg^-1）]	GSH-Px [λ_B/（U·mg^-1）]
Control	1.39±0.13	139.82±7.06	127.09±4.67
Model	2.81±0.20^*	69.28±12.00^*	54.73±6.26^*
Pue	1.76±0.22^△	110.59±9.10^△	100.89±9.92^△
Model+ML385	3.01±0.25	58.45±6.39	43.17±7.38
Pue+ML385	2.08±0.10^#	95.32±8.23^#	81.82±9.09^##

Group	IL-6	IL-1β	TNF-α
Control	16.14±1.05	13.84±1.04	108.50±5.77
Model	28.80±1.44^*	31.07±1.56^*	202.23±9.51^*
Pue	22.65±3.20^△	21.35±1.56^△	143.33±7.78^△
Mod+ML385	31.15±2.06	34.52±1.72	214.49±5.76
Pue+ML385	26.70±0.99^#	23.87±0.99^#	158.76±8.32^#

[1]	Ziyi TANG,Shiying YANG,Tianzhen YANG,Wenqiang LIU,Jiangxue ZHONG,Li YIN. Induction effect of pesticide pyraclostrobin on ferroptosis of spermatocytes GC-2 of mice [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 18-25.
[2]	Huiyan ZHU,Min CHEN,Jinxian LI,Chunli LI. Effect of enriched environment on neurofunctional damage in rats with ischemic stroke via transcription factor EB-mediated autophagy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 116-124.
[3]	Tao SUN,Zhiyin DAI,Xuan LI,Chaopu ZHANG,Shu DING,Jianwei ZHAO. Predictive value of pan-immune-inflammation index for major adverse cardiovascular events within 1 year after PCI in elderly patients with coronary heart disease [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1655-1660.
[4]	Sifan FENG,Yunfeng LI,Jiaying WANG,Fubin MA,Yan WANG. Effects of heme-binding protein 1 gene knockdown on proliferation, migration, and inflammatory response of microglia BV2 and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1532-1541.
[5]	Ying HU,Yong HUANG. Improvement effect of short-chain fatty acids on inflammation-induced autophagic damage in ovarian granulosa cells in polycystic ovary syndrome and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1340-1348.
[6]	Guang YANG,Zhifang ZHENG,Xinhua ZHANG. Research progress in protective effect of miRNA on neonatal hypoxic-ischemic brain injury [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1423-1428.
[7]	Yi ZHAO,Bing ZHOU,Huirui QIU,Xuan LI,Xiangli CUI. Improvement effect of lovastatin on hyperlipidemia-induced liver injury in rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1155-1164.
[8]	Nan LU,Mingxin DONG,Lei YU,Chengbiao SUN,Yan WANG,Na XU,Wensen LIU,Shumin GE. Transcriptome sequencing-based expression profiling of oxidative stress-related genes and circRNAs in ricin toxin-induced macrophage pyroptosis [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1007-1018.
[9]	Lieqian SUN,Mengyu GU,Jie YANG,Kaiyi WANG,Gaoshuai GUO,Hongbo ZHANG,Siyi ZHANG,Tanglong WANG,Zhiwei YANG,Yanni HE,Chao YANG. Effect of bone marrow-derived mesenchymal stem cell transplantation on mitochondrial autophagy in rats with vascular dementia through ROS/Nrf2 signaling and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 610-620.
[10]	Han LIN,Qiuyan YANG,Jieyue ZHONG,Bolun CHEN,Wangxia TONG. Improvement effect of cordycepin on ferroptosis in HepG2 cells induced by RSL3 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 576-589.
[11]	Yue WANG,Ning MA,Jiajun LU,Chengyao WANG,Linyu CHEN,Yuchen REN,Jingwu LI,Hong SUN. Protective effect of novel composite hydrogels on H₂O₂-induced oxidative stress injury in cardiomyocytes [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 352-359.
[12]	Xiaoxia HU,Yalong LI,Dongliang YANG,Bazeren LA,Xinyue LIU. Effect of high glucose on polarization of Raw264.7 macrophages in vitro [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 403-411.
[13]	Junjie JIANG,Hao WU,Kang HE,Zhiqiang SAN,Qing YANG,Hui LI,Na LI. Repair effect of ginseng polypeptide thermosensitive hydrogel on heat-induced skin injury in rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 360-369.
[14]	Chaohe ZHANG,Xinwei ZHANG,Xiangfeng WANG. Protective effect of Pien-Tze-Huang on acetaminophen-induced liver injury and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 105-114.
[15]	Xingqi SU,Lingmin ZHAO,Di MA,Jiulin YOU,Ying CHEN,Liangshu FENG,Jing WANG,Jiachun FENG,Chuan WANG. Analysis on correlation of cerebral infarct area with cytokines and immune status in patients with acute ischemic stroke [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 124-132.